Medicus Pharma Ltd.
MDCX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MDCX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MDCX
Medicus Pharma Ltd. is a clinical-stage, multi-strategy life sciences biotech company focused on accelerating the development of novel therapeutic assets, with lead programs SkinJect (for basal cell carcinoma) and Teverelix (for hormone-sensitive conditions).
Key risk: Going concern risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$16.3M
Cash Runway
10.8 moLead Asset
d-mna (Phase 2)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials · 1 catalyst for Medicus Pharma Ltd..
Medicus Pharma Ltd. is a clinical-stage, multi-strategy life sciences biotech company focused on accelerating the development of novel therapeutic assets, with lead programs SkinJect (for basal cell carcinoma) and Teverelix (for hormone-sensitive conditions).
- Cash and equivalents of $25.2M as of 2026-06-30 [sec].
- Net loss of $11.6M for the period ending 2026-06-30 [sec].
- Shareholders' equity of -$0.1M as of 2026-06-30 [sec].
- Lead pipeline includes SkinJect (Phase II) and Teverelix (Phase II) [sec_mda].
- Going concern uncertainty noted due to history of losses and need for additional capital [sec_mda].
What works
- The company has two clinical-stage programs (SkinJect and Teverelix) advancing in Phase II trials, indicating a diversified pipeline [sec_mda].
- R&D expenses have increased due to clinical trial activity, reflecting active program development [sec_mda].
What to weigh
- Substantial doubt exists about the company's ability to continue as a going concern within one year, based on its history of losses and need for additional capital [sec_mda].
- The company has negative shareholders' equity of -$0.1M as of 2026-06-30 [sec].
- Risks include potential trial failures, lack of FDA approval, or inability to secure future funding [sec_mda].
From the filings
Quoted directly from source documents.
Going concern uncertainty
“This uncertainty, along with the Company's history of losses, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”
SEC MD&A · May 14, 2026
Cash position as of September 30, 2025
“As of September 30, 2025, the Company had cash and cash equivalents of $8,662,091”
SEC MD&A · November 14, 2025
Company description
“The Company is a clinical stage, multi-strategy life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets.”
SEC filings · September 29, 2025
R&D expense increase due to Teverelix and SkinJect
“This increase is primarily due to to the start of the development of Teverelix, offset with a reduction in costs relating to SkinJect as we come to end of its Phase II trials.”
SEC MD&A · May 14, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · skinject — Phase 2 Readout: skinject — Topline data from the Phase 2 trial of SkinJect for basal cell carcinoma is expected, which will inform next development steps.
Risks & what to watch (3)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern within one year due to losses and capital needs [sec_mda].
- Clinical trial failure risk — Trials may be unsuccessful, FDA may not approve next stages, or clinical hold may occur [sec_mda].
- Funding dependency — If unable to secure additional capital, the company may need to delay or reduce R&D programs [sec_mda].
What to watch
- Phase 2 topline readout for SkinJect expected by 2026-12-31 [catalyst].
- Progress of Teverelix Phase II trials and associated R&D spending [sec_mda].
- Ability to raise additional capital to address going concern and fund operations [sec_mda].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Medicus Pharma Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Medicus Pharma Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
10.8 months
OCF -$7M · Net income -$12M
Lead: Phase 2
1 candidate
1 upcoming, next in ~123d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Medicus Pharma Ltd.?
Medicus Pharma Ltd. is a clinical-stage, multi-strategy life sciences biotech company focused on accelerating the development of novel therapeutic assets, with lead programs SkinJect (for basal cell carcinoma) and Teverelix (for hormone-sensitive conditions).
What is Medicus Pharma Ltd.'s lead drug candidate?
Medicus Pharma Ltd.'s most advanced tracked candidate is d-mna (Phase 2) for basal cell carcinoma (BCC) of the skin.
What is Medicus Pharma Ltd.'s next catalyst?
Medicus Pharma Ltd.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: skinject" — expected December 31, 2026.
Who is the CEO of Medicus Pharma Ltd.?
Dr. Raza Bokhari M.B.A., M.D. is the chief executive officer of Medicus Pharma Ltd. (MDCX).
Where is Medicus Pharma Ltd. headquartered?
Medicus Pharma Ltd. (MDCX) is headquartered in West Conshohocken, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.